Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”
Crossref DOI link: https://doi.org/10.1007/s40273-018-0621-x
Published Online: 2018-02-13
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gershon, Noga
Berchenko, Yakir http://orcid.org/0000-0002-9786-4061
Text and Data Mining valid from 2018-02-13
Article History
First Online: 13 February 2018
Compliance with ethical standards
:
: Noga Gershon and Yakir Berchenko declare that they have no competing interests.